SAN CARLOS, Calif., Sept. 2, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has entered into an Exclusive Channel Collaboration (ECC) with Sanofi Chimie, a wholly owned subsidiary of Sanofi (EURONEXT: SAN and NYSE: SNY) to develop an enhanced production process for a specific family of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi's current manufacturing operations in France. This collaboration will leverage Intrexon's proprietary technology suite plus Sanofi's expertise and innovation in yeast metabolism and industrial chemistry to increase overall yield.

Under the ECC, Intrexon will utilize its advanced computational biology and bioinformatics to identify the most efficient biological pathways for producing these marketed APIs. Intrexon's Industrial Product Division facilities in Hungary and California will design and synthesize new components tailored to drive optimal output from constructed cell lines leading to improved process economics. Furthermore, for faster, more efficient collaboration, Intrexon intends to provide ECC partners like Sanofi the ability to remotely access its extensive library of characterized genetic components facilitating customized gene design and high-throughput modular DNA assembly via its new BeyondBio(TM) platform.

"We are excited to partner with Sanofi to improve existing fermentation processes, providing a competitive advantage in marketed APIs production," said Randal J. Kirk, Intrexon Chairman and Chief Executive Officer. "We are confident that our synthetic biology expertise and robust technology platforms will drive development of Sanofi's next-generation strain in a commercially feasible way that also produces the highest possible yields."

About Intrexon Corporation

Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Consumer, Food, Energy, and Environment Sectors to create biologically-based products that improve the quality of life and the health of the planet. Through the company's proprietary UltraVector® platform and suite of technologies, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at


Intrexon, BeyondBio, UltraVector, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:

Intrexon Corporation Contacts:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850

Investor Contact:
Christopher Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052

SOURCE Intrexon Corporation